[{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Otsuka announces positive top-line results from clinical trials in Japan of\\nfremanezumab as a prophylactic treatment for migraine","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Eisai","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Enrolled in Phase II\/III Study of Eisai\u2019s Anti-Mtbr Tau Antibody E2814 For Dominantly Inherited Alzheimer's Disease (DIAD), Conducted By DIAN-TU","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Eisai"}]
Find Neurology Drugs in Phase II/III Clinical Development in JAPAN
An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease modifying agent for tauopathies including sporadic AD. E2814 is designed to prevent the spreading of tau seeds within the brains of affected individuals.
Preliminary trial results indicated that primary endpoints were achieved with statistical significance versus placebo for subjects with chronic migraine and episodic migraine, respectively.